Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lindsey Fath

Nurse Practitioner New Bern, NC Nurse Practitioner

NPI 1891412953 CMS profile 11404369

2111 Neuse Blvd Ste J, New Bern, NC 28560

Open in the dashboard

General payments

$6,510

188 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Fath of New Bern, NC is reported in the CMS Open Payments database as having received $6,510 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,292 59
2024 General $1,134 56
2023 General $3,935 66
2022 General $150 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Fath
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lindsey Fath were reported at $1,292. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lindsey Fath Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $150 $152 $48–$470 $149
2023 $3,935 $166 $54–$529 $160
2024 $1,134 $173 $55–$556 $164
2025 $1,292 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Relievant Medsystems, Inc. $1,589 10 payments
  2. SI-BONE, Inc. $1,443 11 payments
  3. Boston Scientific Corporation $699 26 payments
  4. AbbVie, Inc. $373 21 payments
  5. Collegium Pharmaceutical, Inc. $347 17 payments
  6. Nevro Corp. $224 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $203 11 payments
  8. Vertex Pharmaceuticals Incorporated $160 7 payments
  9. Virtus Pharmaceuticals LLC $150 7 payments
  10. Globus Medical, Inc. $144 8 payments
  11. Other $1,178 59 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,396 181 payments
  2. Travel and Lodging $2,115 7 payments
Products named General payments · program years 2022–2025
  1. Intracept Pain $1,620 12 payments
  2. Intracept Pain $1,589 10 payments
  3. Intracept Pain $1,589 10 payments
  4. Intracept Pain $1,589 10 payments
  5. IFUSE IMPLANT SYSTEM $1,101 6 payments
  6. WaveWriter Alpha Prime 16 $396 17 payments
  7. UBRELVY $272 16 payments
  8. Senza $224 11 payments
  9. BELBUCA $214 11 payments
  10. Intracept Intracept Access Instruments - Additional VB (Gen 3)_NMOD $184 5 payments
  11. Other $2,775 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

3,684

Median for Nurse Practitioner: 389

Drug cost

$206,527

Median for Nurse Practitioner: $21,885

Branded share of claims

42.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 79 $49,331
Nucynta Er Tapentadol Hcl Brand 29 $30,082
Oxycontin Oxycodone Hcl Brand 40 $22,845
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 561 $17,951
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 616 $17,079
Belbuca Buprenorphine Hcl Brand 22 $14,146
Oxycodone Hcl Generic 626 $12,121
Hysingla Er Hydrocodone Bitartrate Brand 14 $11,414
Buprenorphine Generic 29 $6,641
Fentanyl Generic 39 $4,463

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$84,340

Of which drugs: $46

Medicare patients

555

Average age 73

Services billed

2,339

322 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Depression 37%
Chronic kidney disease 27%
Ischemic heart disease 26%
COPD 24%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 56 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $110
$110 — —
BOTOX
  • AbbVie, Inc. $89
$89 — —
LEVORPHANOL TARTRATE
  • Virtus Pharmaceuticals LLC $67
$67 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $67
$67 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $63
$63 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record